Randy Adams

Head of Commercial

Randy is Head of Commercial at Equillium.  He has over 20 years of commercial experience in the specialty pharmaceutical, biological and medical device industries. Most recently, Randy served as Senior Vice President of Commercial at Impact Biomedicines, Inc. where he was responsible for commercial launch preparation for fedratinib, a selective JAK2 inhibitor for the treatment of myelofibrosis.  Previously, Randy was Executive Vice President and Partner at Carling Communications, where he was instrumental in building a global strategic consulting and medical communications agency and was strategic lead on multiple specialty product launches. Prior to Carling Communications, Randy led North America Marketing for Zimmer’s Oral Surgery Division. Prior to joining Zimmer, Randy served in roles of increasing responsibility at Allergan, including Director of Marketing, where he was responsible for leading a $1 billion dry eye portfolio and was instrumental in the launch and successful commercialization of RESTASIS®.  Randy received his Bachelor of Arts in Business Administration from Georgia College & State University.